Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Zacks.com reports.
Separately, Bloom Burton restated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 2nd.
TSE AUP traded down C$0.12 during trading on Thursday, reaching C$6.19. 47,200 shares of the company’s stock were exchanged, compared to its average volume of 54,623. The business has a 50 day moving average price of C$7.29 and a 200-day moving average price of C$8.10. The stock has a market capitalization of $499.35 million and a P/E ratio of -8.88. The company has a debt-to-equity ratio of 0.33, a current ratio of 18.98 and a quick ratio of 18.05. Aurinia Pharmaceuticals has a fifty-two week low of C$4.70 and a fifty-two week high of C$10.47.
Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) last announced its quarterly earnings results on Tuesday, August 6th. The company reported C($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.20) by C($0.03). The business had revenue of C$0.04 million during the quarter, compared to analysts’ expectations of C$0.07 million. On average, analysts forecast that Aurinia Pharmaceuticals will post -0.59 earnings per share for the current year.
In related news, Senior Officer Bradley Dickerson purchased 5,000 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was acquired at an average cost of C$5.11 per share, for a total transaction of C$25,542.00. Following the completion of the purchase, the insider now owns 15,000 shares in the company, valued at approximately C$76,626. In the last 90 days, insiders have bought 9,550 shares of company stock valued at $53,567.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Recommended Story: What is meant by buying and selling pressure?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.